SEC Form 4 · accession 0000899243-15-003911
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 20, 2015 | P | 9,984 | $5.685 | A | 116,719 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,683 shares, with the reporting person's sale of 1,683 shares of common stock at a price of $6.07 per share on August 10, 2015. The reporting person has agreed to pay Keryx $648, representing the full amount of the profit realized in connection with the short-swing transaction.
- F2The reporting person effected multiple same-way open market purchase transactions on the same day at different prices, ranging from $5.68 to $5.71, through a trade order executed by a broker-dealer. The price reported in Column 4 is a weighted average price. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3Includes 63,875 shares of restricted stock.